BioCentury
ARTICLE | Clinical News

Dexmecamylamine: Completed Phase IIb enrollment

February 17, 2014 8:00 AM UTC

Targacept completed enrollment of about 750 patients in a double-blind, placebo-controlled, U.S. Phase IIb trial evaluating 0.5, 1 or 2 mg oral TC-5214 twice daily for 12 weeks (see BioCentury, June 1...